Potencies of human immunodeficiency virus protease inhibitors in vitro against Plasmodium falciparum and in vivo against murine malaria - Test2 - elhamkhani - TriplyDB

Potencies of human immunodeficiency virus protease inhibitors in vitro against Plasmodium falciparum and in vivo against murine malaria

Potencies of human immunodeficiency virus protease inhibitors in vitro against Plasmodium falciparum and in vivo against murine malaria

http://www.wikidata.org/entity/Q24538763

about

Prevalence and clinical features of HIV and malaria co-infection in hospitalized adults in Beira, Mozambique Transition-state inhibitors of purine salvage and other prospective enzyme targets in malaria Adaptive cellular stress pathways as therapeutic targets of dietary phytochemicals: focus on the nervous system Neither the HIV protease inhibitor lopinavir-ritonavir nor the antimicrobial trimethoprim-sulfamethoxazole prevent malaria relapse in plasmodium cynomolgi-infected non-human primates Enzymatic Characterization of Recombinant Food Vacuole Plasmepsin 4 from the Rodent Malaria Parasite Plasmodium berghei The frequency of malaria is similar among women receiving either lopinavir/ritonavir or nevirapine-based antiretroviral treatment HIV protease inhibitors inhibit the development of preerythrocytic-stage plasmodium parasites.A small molecule inhibitor of signal peptide peptidase inhibits Plasmodium development in the liver and decreases malaria severity.HIV protease inhibitors, indinavir or nelfinavir, augment antimalarial action of artemisinin in vitro Expanding the Antimalarial Drug Arsenal-Now, But How?Computational perspectives into plasmepsins structure-function relationship: implications to inhibitors design.RNA interference of Schistosoma mansoni cathepsin D, the apical enzyme of the hemoglobin proteolysis cascade Lopinavir/ritonavir-based antiretroviral treatment (ART) versus efavirenz-based ART for the prevention of malaria among HIV-infected pregnant women Antimalarial effects of human immunodeficiency virus protease inhibitors in rhesus macaques.HIV Protease Inhibitors: Effect on the Opportunistic Protozoan Parasites.Addressing the malaria drug resistance challenge using flow cytometry to discover new antimalarials.In vitro activity of antiretroviral drugs against Plasmodium falciparum Drugs for malaria: something old, something new, something borrowed.Isothermal microcalorimetry accurately detects bacteria, tumorous microtissues, and parasitic worms in a label-free well-plate assay.Synergistic interactions of the antiretroviral protease inhibitors saquinavir and ritonavir with chloroquine and mefloquine against Plasmodium falciparum in vitro.Presence of Plasmodium falciparum DNA in Plasma Does Not Predict Clinical Malaria in an HIV-1 Infected Population HIV-1 protease inhibitors and clinical malaria: a secondary analysis of the AIDS Clinical Trials Group A5208 study An integrative analysis of small molecule transcriptional responses in the human malaria parasite Plasmodium falciparum Saquinavir inhibits the malaria parasite's chloroquine resistance transporter.Antimalarial activity of the anticancer histone deacetylase inhibitor SB939.Pharmacokinetic interactions between artesunate-mefloquine and ritonavir-boosted lopinavir in healthy Thai adults The effect of antiretrovirals on Plasmodium falciparum liver stages Prevalence of asymptomatic parasitemia and gametocytemia among HIV-infected Ugandan children randomized to receive different antiretroviral therapies.Synergy of human immunodeficiency virus protease inhibitors with chloroquine against Plasmodium falciparum in vitro and Plasmodium chabaudi in vivo.Antiretroviral agents and prevention of malaria in HIV-infected Ugandan children.Interactions of different inhibitors with active-site aspartyl residues of HIV-1 protease and possible relevance to pepsin.The Impact of HIV and Malaria Coinfection: What Is Known and Suggested Venues for Further Study.Altered Plasmodium falciparum Sensitivity to the Antiretroviral Protease Inhibitor Lopinavir Associated with Polymorphisms in pfmdr1.Plasmodium falciparum: new molecular targets with potential for antimalarial drug development.Evaluation of Paracheck-Pf(TM) rapid malaria diagnostic test for the diagnosis of malaria among HIV-positive patients in Ibadan, south-western Nigeria.HIV and malaria interactions: where do we stand?Use of quantitative pharmacology tools to improve malaria treatments.Inhibition of Plasmodium Hepatic Infection by Antiretroviral Compounds.N-{(2S)-3-Hy-droxy-4-[(5-methyl-1,3,4-thia-diazol-2-yl)sulfan-yl]-1-phenyl-2-but-yl}-4-methyl-benzene-sulfonamide.Antiretroviral activity of protease inhibitors against Toxoplasma gondii.

P2860

Q21034056-014865DC-B8EC-48B4-997A-19DD721E4D1C Q27014881-195E45CF-BE01-47C1-9E43-03C27459A79E Q28389419-FCE1461C-0270-408C-969D-4CCBA85F5B82 Q28542863-2C0C72DF-3611-43F3-851B-F635DE0D1D6B Q28550537-57017B14-8BA9-435A-886C-7205B1C4D626 Q28730788-D9A91387-11F8-4386-B8FE-D874B5117CDE Q30373475-B5625631-24B3-49A1-ABE9-D64DB18AFABF Q33425212-7591B879-FC59-4EB6-8F8B-6EF191A17EA1 Q33578923-36DD5576-163A-4A28-83E2-8DDE0BCF92FD Q33916111-FC9B13B9-4C69-4BCF-BB36-815345DC8F7D Q33961367-2434C398-FC41-46DD-84C5-B80838282F60 Q34034127-85F3A6FD-AD61-46BE-8587-F7A9CA68A5F7 Q34974794-EC15E4A5-B0E1-4D48-A220-A7EE33AD453E Q35004887-235B6D39-EB63-4C16-8222-58E7BD0E78BB Q35012924-FDACF014-FCD7-4051-8844-A123CC0D3DA7 Q35091523-909811EA-A089-4722-AE51-AB11A2A72EFF Q35363679-FBA2B342-80AE-47B1-888D-BC1421285486 Q35507886-AFB33D3A-8B48-4C13-B57D-8AB89F53CBDA Q35522761-E276BA01-50F6-44E2-98BE-9DC064FBE3FB Q35636034-21AC52E3-D457-4FFD-B9D7-5424C434B07B Q35656242-F7DA776A-A905-47CE-9CBF-BB9EAC8236C5 Q35689395-B7C6339E-DD5A-4F51-9570-5A74A340184B Q35861261-088B7498-4D2B-4A51-9596-B1748A79F3C9 Q35941244-1F368502-9AC9-42C6-B28A-091818D22D76 Q36086326-CEECAD88-7574-4420-A825-1BBAECBE8A8A Q36144257-2263D8A0-356A-40BB-967A-2DDEAEAAC22A Q36664149-377F95E0-EEA7-4581-9B8E-C52B8B033EB0 Q36743880-92A455E1-5C53-408F-97FE-80BDD6617343 Q36744846-6590FAB9-FCC1-422E-9E5B-AAAF098FC215 Q36876420-80A5A8FD-A6BC-4E52-A2A0-21033581A35B Q37286930-BD2663D6-D8BA-4771-8841-4BA303BF48CE Q37297061-F1F66BA1-8FBE-4839-B6F1-050B8642C03A Q37538658-83C83225-A0ED-44B6-8AFA-8A992D7EC913 Q37626063-C1D37C8B-315F-4EBA-B143-9A15BBF14996 Q37726524-5E868B34-839F-46A3-B579-CE21146249A9 Q37984496-F8EB940A-45FF-4021-B08A-2FE38570423D Q38664529-3BAA95FF-5DCD-4315-9F6A-685E6DD202A2 Q38695833-27ADEBAB-9BCD-4B8E-AEE9-63A0124DEF98 Q38813778-CF2ACC2B-3524-4AF7-A6B2-7792BDECB85E Q39264792-E253A5CC-3D4E-418F-A46B-5F8E00E1F958

P2860

Potencies of human immunodeficiency virus protease inhibitors in vitro against Plasmodium falciparum and in vivo against murine malaria

http://www.wikidata.org/entity/Q24538763

description

2006 nî lūn-bûn

@nan

2006 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2006 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

name

Potencies of human immunodefic ...... in vivo against murine malaria

@ast

Potencies of human immunodefic ...... in vivo against murine malaria

@en

Potencies of human immunodefic ...... in vivo against murine malaria

@nl

type

label

Potencies of human immunodefic ...... in vivo against murine malaria

@ast

Potencies of human immunodefic ...... in vivo against murine malaria

@en

Potencies of human immunodefic ...... in vivo against murine malaria

@nl

prefLabel

Potencies of human immunodefic ...... in vivo against murine malaria

@ast

Potencies of human immunodefic ...... in vivo against murine malaria

@en

Potencies of human immunodefic ...... in vivo against murine malaria

@nl

P1433

Q24538763-6654F536-D654-4969-AF6D-0926BB1C91F3

P1476

Q24538763-E5378606-C190-4467-820B-1686A0CD556C

P2093

Q24538763-0C02BC20-8B48-46A5-AE23-48CB93232CFB

Q24538763-292876D0-DFC1-4F32-A621-C6A255F5B850

Q24538763-3609B32A-FF26-4F75-9F91-0FCB986C97D8

Q24538763-41278B55-9FA2-4618-BEC0-112D5020DBB0

Q24538763-5F074AAD-60DC-4B3E-8A59-F92D37981927

Q24538763-68CB7401-BE37-43DA-A467-71D65C3DB70C

Q24538763-7774B678-E11A-448A-B70B-578BBB9F8156

Q24538763-876B82ED-A0AE-4807-AD0E-84B0AEB278D0

Q24538763-C6DD1DDF-7EBD-4555-BF87-3CE2BE2EDECE

Q24538763-D252B720-56CB-45D6-B68F-E24B23F0CF9E

P2860

Q24538763-0F8AC502-EE51-409D-83DF-391A7B9A2281

Q24538763-19D760EA-A940-40BC-9EC4-B84E99B33136

Q24538763-1FF81787-DE2E-46B2-8DB0-13E5D340677D

Q24538763-24B99B43-3278-4A27-BFCF-DA69348CBED9

Q24538763-2BEA1DC9-F77E-4FBD-9599-27485AD76515

Q24538763-31EF5D50-F115-4B15-9714-03FE9ED66971

Q24538763-3948CCC3-F5B2-48A2-802F-A8BA727ECB6A

Q24538763-3DA87ABD-87C6-44E2-AEFD-BF283343A6E6

Q24538763-3E67308A-DCEB-46B2-BAB3-AEFAE3D0D45C

Q24538763-42519D62-F4EC-4098-8563-9A101C5A35AB

P304

Q24538763-0B815441-FDCA-4155-A389-E5432766DB35

P31

Q24538763-3BB37784-4000-4A03-B521-55B6CF0009C4

P356

Q24538763-84C044AA-24DA-4C21-853D-D1E471155A77

P407

Q24538763-BB719756-E1AB-4EAF-A9E4-76F8D58CC7A6

P433

Q24538763-8B9E767B-5021-41DF-88F2-AE8335B2CEC9

P478

Q24538763-75E97975-0135-4F4B-AC37-D32B3899217C

P50

Q24538763-5905606C-4FB2-4436-9CEA-1576B37DE4CA

Q24538763-8DD2E8F2-62D3-4E6D-85C6-E540D5ADDC14

Q24538763-C31FF538-ACB2-4AF8-BA13-ED1DFE0FFC47

Q24538763-E12E8823-FD5B-44E5-B15E-5751C0278223

P577

Q24538763-A2851BDC-90AB-41BB-A031-06E66447ED10

P5875

Q24538763-D3F1683B-A3D1-4796-A6D5-F50DB9643713

P698

Q24538763-51206F53-F846-4358-8F00-1295DC99D2D4

P921

Q24538763-19AEE6AB-6F76-467F-BF78-2A9C592A597F

Q24538763-43627179-F739-455E-AB74-522AC8341B19

P932

Q24538763-2339A36D-38ED-450F-98FA-75A0078302EB

P356

AAC.50.2.639-648.2006

P1433

Antimicrobial Agents and Chemotherapy

P1476

Potencies of human immunodefic ...... in vivo against murine malaria

@en

P2093

David M Wyatt

http://www.w3.org/2001/XMLSchema#string

Donald L Gardiner

http://www.w3.org/2001/XMLSchema#string

James S McCarthy

http://www.w3.org/2001/XMLSchema#string

John Ray

http://www.w3.org/2001/XMLSchema#string

Katherine T Andrews

http://www.w3.org/2001/XMLSchema#string

Lewis A Melville

http://www.w3.org/2001/XMLSchema#string

Lynette Beattie

http://www.w3.org/2001/XMLSchema#string

Petrina M Hilton

http://www.w3.org/2001/XMLSchema#string

Praveen K Madala

http://www.w3.org/2001/XMLSchema#string

Tina Skinner-Adams

http://www.w3.org/2001/XMLSchema#string

P2860

Synthesis, stability, antiviral activity, and protease-bound structures of substrate-mimicking constrained macrocyclic inhibitors of HIV-1 protease

Novel uncomplexed and complexed structures of plasmepsin II, an aspartic protease from Plasmodium falciparum

ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humans

Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings

Plasmodium hemozoin formation mediated by histidine-rich proteins

Human malaria parasites in continuous culture

Prediction of binding constants of protein ligands: a fast method for the prioritization of hits obtained from de novo design or 3D database search programs

Rational design of peptide-based HIV proteinase inhibitors

BMS-232632, a highly potent human immunodeficiency virus protease inhibitor that can be used in combination with other available antiretroviral agents

Saquinavir and ritonavir pharmacokinetics following combined ritonavir and saquinavir (soft gelatin capsules) administration

P304

639-648

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/AAC.50.2.639-648.2006

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

50

http://www.w3.org/2001/XMLSchema#string

P50

David P. Fairlie

Martin J Stoermer

P577

2006-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7336403

http://www.w3.org/2001/XMLSchema#string

P698

16436721

http://www.w3.org/2001/XMLSchema#string

P921

Plasmodium falciparum

P932

1366900

http://www.w3.org/2001/XMLSchema#string